Hanneke van der Gulden
The Netherlands Cancer Institute(NL)Oncode Institute(NL)
Publications by Year
Research Areas
CRISPR and Genetic Engineering, BRCA gene mutations in cancer, DNA Repair Mechanisms, Biotechnology and Related Fields, PARP inhibition in cancer therapy
Most-Cited Works
- → Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer(2001)1,058 cited
- → 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers(2010)1,017 cited
- → Induction of medulloblastomas inp53-null mutant mice by somatic inactivation ofRbin the external granular layer cells of the cerebellum(2000)931 cited
- → Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis(2006)592 cited
- → Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer(2007)478 cited
- → The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin(2016)267 cited
- → BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance(2011)262 cited
- → BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1(2016)138 cited
- → A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants(2013)134 cited
- → Frat is dispensable for canonical Wnt signaling in mammals(2005)70 cited